文献速递姑息放疗与转移瘤放疗物理与技术

寡转移性疾病立体定向体部放疗的癌种特异性剂量与分割方案:EORTC-ESTRO E2-RADIatE OligoCare 研究的中期分析

Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study.
PubMed 文献 · Radiother Oncol · 2024-03-19

该中期分析基于 OligoCare 研究前 1099 例注册患者,分析寡转移癌患者接受立体定向体部放疗(SBRT)时剂量与分割方案的相关因素。多因素分析显示,SBRT 剂量随原发癌种和转移部位显著变化,肺和肝病灶剂量更高。作者认为真实世界数据显示 SBRT 剂量会根据原发癌和寡转移部位进行调整。

要点

  • 999 例符合纳入标准并接受转移灶 SBRT,其中非小细胞肺癌 195 例、乳腺癌 163 例、结直肠癌 184 例、前列腺癌 457 例。
  • 中位分割次数为 5 次(IQR 3-5),中位单次剂量为 9.7 Gy(IQR 7.7-12.4 Gy)。
  • 多因素分析显示剂量随原发癌种和转移部位显著变化,肺和肝病灶剂量更高。

核心结论

  • 真实世界分析提示 SBRT 剂量会根据原发癌种和寡转移部位进行调整。
  • 未来分析将评估这种按部位和疾病调整的 SBRT 分割方案的安全性和有效性(NCT03818503)。

研究设计与样本

  • OligoCare 研究的中期分析,基于前 1099 例注册患者。
  • SBRT 剂量按 α/β 转换为生物有效剂量(BED):所有原发癌用 α/β=10 Gy,非小细胞肺癌和结直肠癌用癌种特异性 α/β=10 Gy,乳腺癌用 2.5 Gy,前列腺癌用 1.5 Gy。

主要发现

  • 999 例(99.5%)符合纳入标准并接受转移灶 SBRT:非小细胞肺癌 195 例(19.5%)、乳腺癌 163 例(16.3%)、结直肠癌 184 例(18.4%)、前列腺癌 457 例(47.5%)。
  • 三分之二患者针对单个转移灶治疗。
  • 中位分割次数为 5 次(IQR 3-5),中位单次剂量为 9.7 Gy(IQR 7.7-12.4 Gy)。
  • 最常治疗部位为非椎体骨(22.8%)、肺(21.0%)和远处淋巴结转移(19.0%)。
  • 多因素分析中剂量随原发癌种显著变化(乳腺癌:237.3 Gy BED,前列腺癌:300.6 Gy BED,结直肠癌:84.3 Gy BED),并随转移部位变化,肺和肝病灶剂量更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND INTRODUCTION: Optimal dose and fractionation in stereotactic body radiotherapy (SBRT) for oligometastatic cancer patients remain unknown. In this interim analysis of OligoCare, we analyzed factors associated with SBRT dose and fractionation. MATERIALS AND METHODS: Analysis was based on the first 1,099 registered patients. SBRT doses were converted to biological effective doses (BED) using α/β of 10 Gy for all primaries, and cancer-specific α/β of 10 Gy for non-small cell lung and colorectal cancer (NSCLC, CRC), 2.5 Gy for breast cancer (BC), or 1.5 Gy for prostate cancer (PC). RESULTS: Of the interim analysis population of 1,099 patients, 999 (99.5 %) fulfilled inclusion criteria and received metastasis-directed SBRT for NSCLC (n = 195; 19.5 %), BC (n = 163; 16.3 %), CRC (n = 184; 18.4 %), or PC (n = 457; 47.5 %). Two thirds of patients were treated for single metastasis. Median number of fractions was 5 (IQR, 3-5) and median dose per fraction was 9.7 (IQR, 7.7-12.4) Gy. The most frequently treated sites were non-vertebral bone (22.8 %), lung (21.0 %), and distant lymph node metastases (19.0 %). On multivariate analysis, the dose varied significantly for primary cancer type (BC: 237.3 Gy BED, PC 300.6 Gy BED, and CRC 84.3 Gy BED), and metastatic sites, with higher doses for lung and liver lesions. CONCLUSION: This real-world analysis suggests that SBRT doses are adjusted to the primary cancers and oligometastasis location. Future analysis will address safety and efficacy of this site- and disease-adapted SBRT fractionation approach (NCT03818503).

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Christ SM, Alongi F, Ricardi U, et al. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiother Oncol. 2024. PMID: 38508239. doi:10.1016/j.radonc.2024.110235

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。